Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary.

Slides:



Advertisements
Similar presentations
Lipid-altering Efficacy and Safety Profile of Co-administered Extended Release Niacin/Laropiprant and Simvastatin in Patients With Dyslipidemia Gilbert.
Advertisements

Henry C. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.
A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of a Monoclonal Antibody to PCSK9, SAR236553/REGN727, in Patients with.
The LAPLACE-2 Trial: A Phase 3, Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy.
Simvastatin Increases HDL-C and Apolipoprotein A-1 Levels Significantly More Than Atorvastatin John P. Kastelein, Evan A. Stein, Michael A. Davidson, John.
Henry N. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.
An Academic Research Organization of Brigham and Women’s Hospital and Harvard Medical School LAPLACE-TIMI 57 Primary Results A Double-blind, Randomized,
Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study Michael J.
CE-1 CRESTOR ® Clinical Development Efficacy James W. Blasetto, MD, MPH Senior Director, Clinical Research.
Lipid-Modulating Effects of Evacetrapib, a Novel CETP Inhibitor, Administered as Monotherapy or in Combination with the Most Commonly-Used Statins SJ.
Downloaded from Slide 1 Ezetimibe Coadministered with Atorvastatin in Patients with Hypercholesterolemia and Coronary Heart.
Role of Rosuvastatin in the Treatment of Dyslipidemia
ACCP Cardiology PRN Journal Club
Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD): Results from a Phase 2, Randomized, Double-Blind,
Efficacy and Safety of Evolocumab (AMG 145) Monotherapy Compared With Ezetimibe and Placebo in Hypercholesterolemic Subjects: A Phase 3 Randomized Clinical.
Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a Randomized, Double-blind, Placebo-Controlled.
Tadalafil for the Treatment of Pulmonary Arterial Hypertension: A Double-blind 52-week Uncontrolled Extension Study Ronald J. Oudiz, MD, FACC; Bruce H.
Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production in Patients with Type 2 Diabetes.
Slide 1 EZT 2002-W-6022-SS Ezetimibe Co-administered with Statins: Efficacy and Tolerability Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.
Efficacy and Safety of the PCSK9 Monoclonal Antibody Alirocumab versus Placebo in 1257 Patients with Heterozygous Familial Hypercholesterolaemia: Analyses.
Praluent® - alirocumab
Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results SJ Nicholls,
Slide 1 Downloaded from Ezetimibe Factorial Coadministration Studies.
CI-1 CRESTOR ® (rosuvastatin calcium) Tablets Endocrinologic and Metabolic Drugs Advisory Committee Bethesda, Maryland July 9, 2003 C.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
1 ALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 Synthesis With the Potential for Effective Bi-Annual Dosing: Interim Results Kevin Fitzgerald,
Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.
Results of the First Major Clinical Trial of An Oral Agent Inducing ApoA-I Synthesis: A New Approach to Raising HDL and CV Risk Modification SJ Nicholls,
Manufacturer: Amgen Inc FDA Approval Date: August 27, 2015
Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production Results of a Clinical Trial.
J Am Coll Cardiol. 2015;65(24): doi: /j.jacc Figure Legend:
Kendrick Sparks, PGY3 September 17, 2015
Steven E. Nissen MD MACC*
Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome
Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Test in Context: High-Sensitivity C-Reactive Protein.
R1. 이정미 / prof. 김우식. INTRODUCTION Reduction in low-density lipoprotein (LDL) cholesterol levels has proved to be highly effective in reducing rates of.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Redefining Normal Low-Density Lipoprotein Cholesterol:
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.
Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis: Insights from the GLAGOV Trial SJ Nicholls, H Kassahun, DM Brennan,
Christie M. Ballantyne, MD
Evolocumab Drugbank ID : DB09303.
Update on the Role of PCSK9 in the Treatment of the High-Risk CVD
Do PCSK9 Inhibitors Cause Cognitive Impairment?
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
The LAPLACE-2 Trial: A Phase 3, Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy.
Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.
Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,
62-year-old Man With Unstable Angina
% decrease in LDL-C at 24 weeks from baseline
% decrease in LDL-C at 24 weeks from baseline
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia  Joep C. Defesche, PhD,
Radical New Concepts in Lipid Management
A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia  Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.
Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.
Screening, Lipid Stabilization, and Placebo Run-in
Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment.
Efficacy and safety of niacin/laropiprant
To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B?  Carl J. Lavie, MD, Richard V. Milani, MD, James.
RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
The LAPLACE-2 Trial: A Phase 3, Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy.
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies.
in diabetic patients with mixed dyslipidemia
LDL-c reductions below 1
Presentation transcript:

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy James M. McKenney, PharmD; Michael J. Koren, MD, FACC, CPI; Dean J. Kereiakes, MD, FACC, FSCAI; Corinne Hanotin, MD; Anne-Catherine Ferrand, MSc; and Evan A. Stein, MD, PhD

Disclosures  J.M.M. is an employee of a research company that has received research funding from Regeneron and Sanofi  M.J.K. received no financial benefit for his contributions to this manuscript, but is an employee of a research organization that receives research funding from Regeneron and Sanofi  C.H. and A.-C.F. are both employees of Sanofi  E.A.S. is affiliated with the Metabolic and Atherosclerosis Research Center, and Medpace Research Laboratories. He has received research grants related to trials of REGN727/SAR from Regeneron and Sanofi, as well as consultancy fees from Sanofi. In addition, he has received grants for trials of numerous lipid-modifying agents, consultancy fees, and honoraria for professional input regarding lipid-altering agents, and/or has delivered lectures for AACC, Abbott, Amgen, AstraZeneca, Bristol-MyersSquibb, FDA, F. Hoffman La Roche, Genentech, Genzyme, GSK, ISIS, Merck & Co., the National Lipid Association, Novartis, Sankyo, Schering-Plough, and Wyeth.  Financial support: This study was financially supported by Sanofi US, Bridgewater, New Jersey, and Regeneron Pharmaceuticals Incorporated, Tarrytown, New York.

Objectives  The primary objective of this study was to evaluate the low-density lipoprotein cholesterol (LDL-C)- lowering efficacy of 5 REGN727/SAR (SAR236553) dosing regimens versus placebo at week 12 in patients with LDL-C ≥100 mg/dL on stable atorvastatin therapy.  Secondary objectives included evaluation of effects on other lipid parameters and the attainment of LDL-C treatment goals of <100 mg/dL (2.59 mmol/L) and <70 mg/dL (1.81 mmol/L). J Am Coll Cardiol 2012;59:

Background  Serum proprotein convertase subtilisin kexin 9 (PCSK9) binds to LDL, increasing serum LDL-C.  SAR is a fully human monoclonal antibody to PCSK9. J Am Coll Cardiol 2012;59:

Methods  This double-blind, parallel-group, placebo- controlled trial randomized 183 patients with LDL-C ≥100 mg/dL (2.59 mmol/L) on stable-dose atorvastatin 10, 20, or 40 mg for ≥6 weeks to: subcutaneous placebo every 2 weeks (Q2W); SAR , 100, or 150 mg Q2W; or SAR or 300 mg every 4 weeks (Q4W) alternating with placebo for a total treatment period of 12 weeks. J Am Coll Cardiol 2012;59:

Results  SAR demonstrated a clear dose-response relationship with respect to percentage LDL-C lowering for both Q2W and Q4W administration: 40%, 64%, and 72% with 50, 100, and 150 mg Q2W, respectively 43% and 48% with 200 and 300 mg Q4W LDL-C reduction with placebo at week 12 was 5%  SAR also substantially reduced non-HDL cholesterol, apolipoprotein B, and lipoprotein(a)  SAR was generally well tolerated  One patient on SAR experienced a serious adverse event of leukocytoclastic vasculitis J Am Coll Cardiol 2012;59:

Change in Calculated LDL-C from Baseline to Week 12 by Stratified Atorvastatin Dose J Am Coll Cardiol 2012;59:

Change in Calculated LDL-C at 2-Week Intervals from Baseline to Week 12 J Am Coll Cardiol 2012;59:

Attainment of Treatment Targets for LDL-C, Non-HDL-C, and Apo-B J Am Coll Cardiol 2012;59:

Conclusions  When added to atorvastatin, PCSK9 inhibition with SAR further reduces LDL-C by 40-72%.  These additional reductions are both dose- and dosing frequency-dependent. J Am Coll Cardiol 2012;59:

Clinical Trial Identifier: Efficacy and Safety Evaluation of SAR (REGN727) in Patients With Primary Hypercholesterolemia and LDL-cholesterol on Stable Atorvastatin Therapy